福建基诺厚普生物科技

Genope Biotechnology is a clinical-stage biopharmaceutical company based in Fuzhou, China, specializing in the development of innovative adoptive cell therapies for cancer. The company focuses on three primary technology pillars: CAR-T, TCR-T, and TIL (Tumor-Infiltrating Lymphocyte) therapies, targeting both hematological malignancies and refractory solid tumors. Its lead programs include multi-target CAR-T cells for B-cell lymphomas and TCR-engineered T cells for liver cancer. Genope operates integrated R&D centers and GMP-compliant manufacturing facilities to support its clinical pipeline. The company aims to address unmet medical needs in oncology by enhancing the precision and persistence of engineered immune cells within the tumor microenvironment.